Previous research has indicated a pooled sensitivity for mutated GNAS in PCF of 46% (39–56%) in mucinous neoplasms and 56% (45–66%) in IPMN through DNA-targeted sequencing (15,16,18–23). The gene discussed is GNAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.